Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:PEN
Previous Symbol
CUSIPN/A
Phone510-748-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio6.11
Quick Ratio4.43
Price-To-Earnings
Trailing P/E Ratio-13,657.00
Forward P/E Ratio290.57
P/E Growth13.68
Sales & Book Value
Annual Sales$333.76 million
Price / Sales14.12
Cash Flow$0.1292 per share
Price / Cash1,057.21
Book Value$11.86 per share
Price / Book11.52
Profitability
EPS (Most Recent Fiscal Year)($0.01)
Net Income$4.65 million
Net Margins2.15%
Return on Equity4.21%
Return on Assets3.53%
Miscellaneous
Employees1,700
Outstanding Shares34,500,000
Market Cap$4.48 billion
OptionableOptionable
Penumbra (NYSE:PEN) Frequently Asked Questions
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra Inc (NYSE:PEN) released its quarterly earnings results on Monday, November, 5th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.14. The business had revenue of $111.80 million for the quarter, compared to analyst estimates of $103.59 million. Penumbra had a net margin of 2.15% and a return on equity of 4.21%. Penumbra's revenue for the quarter was up 33.3% compared to the same quarter last year. During the same period last year, the firm earned $0.01 earnings per share. View Penumbra's Earnings History.
When is Penumbra's next earnings date?
What price target have analysts set for PEN?
8 brokers have issued 1-year price targets for Penumbra's shares. Their forecasts range from $36.00 to $180.00. On average, they anticipate Penumbra's stock price to reach $143.6667 in the next year. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Price Targets for Penumbra.
What is the consensus analysts' recommendation for Penumbra?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Penumbra.
What are Wall Street analysts saying about Penumbra stock?
Here are some recent quotes from research analysts about Penumbra stock:
- 1. According to Zacks Investment Research, "Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. " (11/7/2018)
- 2. Canaccord Genuity analysts commented, "We followed up with management this morning and discerned several noteworthy details about the firm’s newest aspiration system. PEN’s newest aspiration catheter includes three critical improvements and upgrades to PEN’s own ACE 68 catheter, further distancing and differentiating PEN from the competition in clot aspiration within the acute ischemic stroke market, in our view: 1. Larger diameter – JET 7 has the largest internal diameter of any aspiration catheter ever cleared – 0.72 inner diameter compared to PEN’s previous 0.68 catheter (Ace 68) – with JET 7’s larger diameter driving a significant increase in the number of cases in which the entire is able to be aspirated almost immediately (within 1-2 minutes)." (8/20/2018)
Has Penumbra been receiving favorable news coverage?
News coverage about PEN stock has trended very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Penumbra earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), ICU Medical (ICUI), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR) and Glaukos (GKOS).
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 56)
- Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 56)
- Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 40)
- Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 57)
- Mr. Daniel Donen Davis, Chief Commercial Officer & Pres of North America (Age 40)
Who are Penumbra's major shareholders?
Penumbra's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.53%), Alliancebernstein L.P. (2.34%), Partner Fund Management L.P. (2.10%), Putnam Investments LLC (2.05%), Baillie Gifford & Co. (1.93%) and Franklin Resources Inc. (1.07%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.
Which institutional investors are selling Penumbra stock?
PEN stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., Renaissance Technologies LLC, Jane Street Group LLC, Capital Fund Management S.A., Mutual of America Capital Management LLC, Carret Asset Management LLC and Prudential Financial Inc.. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Insider Buying and Selling for Penumbra.
Which institutional investors are buying Penumbra stock?
PEN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Partner Fund Management L.P., Redmile Group LLC, Los Angeles Capital Management & Equity Research Inc., Putnam Investments LLC, Baillie Gifford & Co., Franklin Resources Inc. and Credit Suisse AG. View Insider Buying and Selling for Penumbra.
How do I buy shares of Penumbra?
Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of PEN stock can currently be purchased for approximately $136.57.
How big of a company is Penumbra?
Penumbra has a market capitalization of $4.48 billion and generates $333.76 million in revenue each year. The company earns $4.65 million in net income (profit) each year or ($0.01) on an earnings per share basis. Penumbra employs 1,700 workers across the globe.
What is Penumbra's official website?
How can I contact Penumbra?
Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]
MarketBeat Community Rating for Penumbra (NYSE PEN)
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
